Examination of utility of bisphosphonate to osteoporosis by ovarian insufficiency after gynecologic cancer treatment

Trial Profile

Examination of utility of bisphosphonate to osteoporosis by ovarian insufficiency after gynecologic cancer treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2015

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Bone resorption; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 May 2015 Status changed from not yet recruiting to completed as per University Hospital Medical Information Network - Japan.
    • 03 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top